亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells.

医学 嵌合抗原受体 更昔洛韦 免疫系统 前列腺癌 抗原 胸苷激酶 癌症研究 免疫学 T细胞 癌症 内科学 单纯疱疹病毒 病毒 人巨细胞病毒
作者
Susan F. Slovin,Xiuyan Wang,Oriana Bórquez-Ojeda,Jolanta Stefanski,Malgorzata Olszewska,Clare Taylor,Shirley M. Bartido,Howard I. Scher,Michel Sadelain,Isabelle Rivière
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:30 (15_suppl): TPS4700-TPS4700 被引量:8
标识
DOI:10.1200/jco.2012.30.15_suppl.tps4700
摘要

TPS4700 Background: Based on our preclinical animal models, we initiated a phase I dose-escalating study to assess safety, dose requirement and targeting efficiency of genetically directed autologous human T cells targeted to Prostate Specific Membrane Antigen (PSMA). Our approach is based on the infusion of autologous PSMA-targeted T cells utilizing the P28z second generation chimeric antigen receptor (CAR) in patients (pts) with metastatic CRPC, following iv cyclophosphamide (Cy) (trial NCT01140373). For safety, the herpes simplex virus-1 thymidine kinase (hsvtk) gene is co-expressed with the P28z receptor, and renders T cells sensitive to ganciclovir for immediate T cell elimination if needed. The expression of hsvtk enables PET imaging using radiolabeled FIAU to localize adoptively transferred T cells. The aims of the trial are to assess: (1) safety of PSMA-targeted T cells; (2) biologic and anti-tumor effects; (3) T cell persistence at tumor site; and (4) immune response. Methods: Autologous T cells are activated from a leukapheresis product using anti-CD3/CD28 Dynabeads. Release criteria include mean vector copy number by Q-PCR and vector identity by Southern blot, absence of Replication Competent Retrovirus and residual Dynabeads. Pts will be treated at 3 dose levels from 107 to 108 CAR+ T cells/kg. Four patients have been enrolled; 3 have been treated with 300mg/m2 of Cy one day before infusion of 107 CAR+ T cells/kg. Pts underwent baseline and post treatment CT, bone and PET scans. Pts are followed weekly, then monthly with blood work including immune and vector sequence monitoring. Results: The first 3 pts within the first cohort were successfully treated without toxicity. Two had stable disease for greater than 6 months with the third patient having disease progression. There were no acute adverse events. Conclusion: We have established an ex vivo transduction, expansion and therapeutic protocol for the generation and testing of safe, clinical-grade, PSMA targeted T cells. Pts enrolled at the next dose level of 3 x 107 CAR+ T cells/kg will be assessed as described and by imaging the transduced T cell population using 18F-FIAU as a radiotracer. The data pertaining to the planned T cell imaging will be presented as well.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大模型的应助被369ninja采纳,获得10
12秒前
15秒前
369ninja发布了新的文献求助10
19秒前
懦弱的代云完成签到,获得积分10
29秒前
如意涵雁完成签到,获得积分10
34秒前
华仔的应助被爱学习的doge采纳,获得10
36秒前
英姑的应助被爱学习的doge采纳,获得10
49秒前
52秒前
52秒前
53秒前
58秒前
59秒前
59秒前
韩_发布了新的文献求助10
1分钟前
彭于晏的应助被科研通管家采纳,获得10
1分钟前
充电宝的应助被sun采纳,获得10
1分钟前
1分钟前
甜甜的文轩完成签到,获得积分10
1分钟前
爱笑的芝麻完成签到,获得积分10
1分钟前
阿双完成签到,获得积分10
1分钟前
sun发布了新的文献求助10
1分钟前
1分钟前
2分钟前
灵巧的绮琴完成签到,获得积分10
2分钟前
整齐的天问完成签到,获得积分10
2分钟前
Qian完成签到 ,获得积分10
2分钟前
细腻绮完成签到,获得积分10
2分钟前
2分钟前
天天快乐的应助被情深以挽采纳,获得10
2分钟前
369ninja发布了新的文献求助10
2分钟前
玛琳卡迪马完成签到,获得积分10
2分钟前
molihuakai的应助被科研通管家采纳,获得10
3分钟前
3分钟前
英俊的谷蓝完成签到,获得积分10
3分钟前
明理的璎完成签到,获得积分10
3分钟前
3分钟前
美丽的忆彤完成签到,获得积分10
3分钟前
Ava的应助被sun采纳,获得10
3分钟前
3分钟前
动听一德完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808444
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557352
邀请新用户注册赠送积分活动 2478958